

GUIDELINES FOR THE DIAGNOSIS OF THE HAEMOGLOBINOPATHIES IN NIGERIA

Taiwo R. Kotila

Department of Haematology, University of Ibadan, Nigeria

Correspondence:

Dr. T.R. Kotila

Department of Haematology,
University College Hospital,
PMB 5116, Ibadan, Nigeria
Email: tkotila@comui.edu.ng

ABSTRACT

The haemoglobinopathies are prevalent genetic disorders in Nigeria, it is therefore imperative that diagnosis is made accurately and promptly so that affected individuals can seek timely medical help. There is no structured modality for the investigation of the haemoglobinopathies in the country. Haemoglobin electrophoresis at alkaline pH is solely relied upon by both the secondary and tertiary health centres in the diagnosis of the haemoglobinopathies. It is also necessary to know and understand the various diagnostic tests available for this genetic disorder and to interpret the results correctly. This review discusses the different diagnostic tests appropriate for the different levels of health care in the country.

INTRODUCTION

The haemoglobinopathies are a group of inherited disorders of haemoglobin synthesis and are divided into five broad groups which include, structural (qualitative), quantitative (Thalassaemias), unstable haemoglobins, haemoglobins with low oxygen affinity and the M haemoglobins which are associated with familial cyanosis while haemoglobins with high oxygen affinity are associated with erythrocytosis (polycythaemia). Accurate diagnosis of the haemoglobinopathies is necessary in this environment not because it is a prevalent condition but also because even though there are over 400 haemoglobin variants not all are symptomatic. Most haemoglobinopathies are due to one or two amino acid substitutions thus affecting the mobility of the haemoglobin on electrophoresis. This aids easy diagnosis of these disorders. There are a number of clinically significant haemoglobins which do not alter the overall charge of the protein so are detected by other methods other than electrophoresis, e.g. isoelectric focusing, high- performance liquid chromatography (HPLC), and immunologic techniques.

Sickle cell disease (SCD) is a haemoglobinopathy with structural defect and it is very common in Nigeria. The prevalence of homozygous SCD (HbSS) and HbS+C disease is 3.1% and 1.1% respectively thus giving a combined prevalence of 4.1% while the trait (HbAS) has a prevalence of 23.7%¹. This high prevalence requires that accurate diagnosis of the disorder is made, not only at the tertiary hospitals but also at the secondary level while primary health centres should be able to screen patients for the disorder.

The thalassaemias are quantitative disorders of haemoglobin synthesis which are classified into two; the alpha and the beta thalassaemias. The single deletion alpha thalassaemia which is common² in this environment is the mild type but beta thalassaemia which is of more clinical significance was initially thought to be of low prevalence³ but it is now known to be of high prevalence^{4,5}. There is therefore the need to be able to differentiate these various haemoglobinopathies and treat the patients' accordingly. Accurate diagnosis will also prevent subjecting the patients to unnecessary investigations.

The objective of this write up is to provide a guideline for the screening and diagnosis of the haemoglobinopathies in the Nigerian setting and to delineate what tests are appropriate for the different level of health care.

Patient Selection

Patients who present with unexplained anaemia should be screened for haemoglobinopathy and it should be mandatory to rule out a haemoglobinopathy especially in patients presenting with moderate or severe anaemia in the presence of jaundice⁵. Patients noticed to have microcytosis and hypochromia on blood film review, should be investigated for thalassaemia more so if a trial of iron therapy does not correct this blood film appearance. The nation is however ripe for newborn screening of these prevalent disorders; this will help in reducing the morbidity and mortality associated with them.

Screening Tests

Microscopy: A review of the peripheral blood film is a good initial screening test, the presence of target cells and sickled erythrocyte or microcytic cell is a pointer to sickle cell disease or thalassaemia respectively.

Sickling test: This is a simple screening test that can be done especially in a primary health care facility. A drop of blood is mixed with two drops of 2% sodium metabisulphite, this is then covered with a coverslip and sealed with petroleum jelly. The slide is then examined under the microscope after 15 minutes, one hour and 24 hours⁶. The presence of sickled erythrocytes in a patient with symptoms of sickle cell disease is suggestive of the disorder. False positive results may occur if sodium metabisulphite of greater than 2% is used while false negative results may occur if the metabisulphite is stale and also in the neonatal period because of the low percentage of HbS.

Solubility test: This is based on the fact that HbS is less soluble than HbA in the deoxygenated state. One drop of the patient's blood is mixed with a solution prepared using potassium dihydrogen phosphate, dipotassium hydrogen phosphate and sodium metabisulphite. The mixture is spun in a centrifuge; HbS if present, precipitates as a red opaque band on the surface of the test solution while other haemoglobins remain in solution⁶. Control blood samples with HbA, HbAS and HbS should be tested at the same time. There are commercial test kits now available for this procedure. Solubility test should be performed on all samples which showed the "S" band on alkaline electrophoresis especially in our environment in which haemoglobins G and D which comigrate with HbS on alkaline electrophoresis is present.

Haemoglobin Electrophoresis

In an alkaline buffer, HbA is a negatively charged protein which moves toward the positive electrode (anode) in an electric field. Most haemoglobin variants are separated from HbA during electrophoresis because the structural abnormality usually involves changes in electrical charge while haemoglobin without a change in charge will not separate. The pH and medium used are varied in order to identify the different haemoglobin variants; electrophoresis for haemoglobin identification is commonly run with cellulose acetate paper at alkaline pH and/or citrate agar at acidic pH.

Cellulose acetate electrophoresis at alkaline pH: Cellulose acetate paper as support medium and at a pH of 8.4-8.9 has the advantage of rapid separation of haemoglobins, ease of handling and minimal prepara-

tive work. Its disadvantages are that haemoglobin fractions in low concentration like HbA₂, HbH and Hb Bart's may be missed. Also when small haemoglobin fractions occur near a broad band, the minor fraction may be missed especially in neonates when high levels of HbF can cause the presence of either HbA or HbS to be missed. Certain haemoglobins which comigrate at this pH include HbS, HbD and HbG, at this pH HbA₂, HbC, HbE and HbO also comigrate.

Citrate agar electrophoresis at acidic pH: Separation of haemoglobin variants by this method is determined by the relative affinity for agarosectin by certain haemoglobin surface groups. It is performed at a pH of 6.0-6.2 and it delineates haemoglobins that comigrate at alkaline pH and other cases that cannot be resolved at alkaline pH. It is particularly useful in diagnosing sickle cell disease at birth when the high concentration of HbF may pose a problem. It is however technically difficult to handle. Haemoglobins A, D, E, G, H all comigrate at this pH.

Isoelectric focusing: This is a high resolution method for separating proteins according to their isoelectric points, i.e. points at which the net charge is zero. Separation of haemoglobins by this method is similar to that obtained by electrophoresis on cellulose acetate except that the bands are sharper and the resolution of some haemoglobins are better.

Diagnosis of the Thalassaemias

Red cell indices are particularly useful in screening for the thalassaemias and this is best done by an automated blood cell counter. Beta thalassaemia trait (BTT) is associated with mild or no anaemia but with reduced mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), values and an elevated haemoglobin A₂ (HbA₂) level^{7,8}, normal red cell indices may however be found in people with + thalassaemia trait⁹ or silent + trait⁷. The diagnosis of

thalassaemia is often made following exclusion of thalassaemia and/or iron deficiency; since most cases of alpha thalassaemia are of the clinically benign type (i.e. + thalassaemia). It should be noted that the red cell indices may also be affected by concomitant B12 deficiency, folate deficiency or liver abnormalities with such people having normal red cell indices. Also in the Nigerian population where the prevalence of alpha thalassaemia is equally high, normal red cell indices does not rule out Beta thalassaemia trait since there may not be the expected alpha/ beta chain imbalance.

To make a diagnosis of thalassaemia trait therefore, the following tests should be done (a) electrophoresis of haemoglobin on cellulose acetate membrane at al-

kaline pH; (b) measurement of HbA₂; (c) assessment of HbF; (d) checking for HbH inclusion bodies and (e) assessment of iron status.

Quantitative estimation of HbA₂: There are many methods for estimating HbA₂ but the elution method after electrophoresis with cellulose acetate paper is still generally acceptable and reliable¹⁰. A raised HbA₂ is the hallmark of the classic beta thalassaemia trait⁷. Any HbA₂ variant present should be eluted with the A₂. Values below 3.3% are usually normal and over 3.7% usually indicate the Beta thalassaemia trait. Overlap in HbA₂ values between normal and Beta thalassaemia have been reported¹¹, therefore values between 3.3 and 3.7% should be interpreted with care while a value above 7% suggests an analytical error or the presence of another haemoglobin that is not A₂. Concomitant iron deficiency may result in classifying a person with Beta thalassaemia as not having the condition since iron deficiency may cause a low level of HbA₂¹², thus necessitating an assessment of the patient's iron status. The HbA₂ should then be rechecked after iron therapy.

Assessment of HbF: This is traditionally measured by the two minute denaturation technique of Betke¹³. Recent methods include radial immunodiffusion, Eliza and by HPLC. HbF is below 1% in the healthy adult but values between 1-3% are found in a third to half of the patients with Beta thalassaemia trait⁷. A raised value of over 5% in the presence of hypochromia and microcytosis is suggestive of $\alpha\alpha$ thalassaemia but if the value of HbF is higher than 20% the distribution of the HbF in the cell is checked for by Kleihauer cytochemical test. This will help differentiate High persistence of HbF (HPHF) from $\alpha\alpha$ thalassaemia.

Hb H inclusion bodies: The presence of Hb H inclusion bodies is better observed in slides prepared from fresh blood stained with supravital stains like brilliant cresyl blue or new methylene blue and it indicative of alpha thalassaemia. Red cells with inclusion bodies are fewer in people with alpha thalassaemia trait than in people with Hb H disease. The absence of Hb H inclusion does not, however, exclude an alpha thalassaemia trait.

Iron status: Iron deficiency anaemia is a differential diagnosis of hypochromic, microcytic anaemia; it can also be a reason for a low HbA₂ in a patient with beta thalassaemia trait. It may therefore be necessary to know the iron status of a patient suspected of having thalassaemia trait. Red cell indices and formulae derived from them have not been useful in differentiating between beta thalassaemia trait and iron deficiency^{8,14,15}. Studies done in the Nigerian population have shown normal iron levels in healthy, pregnant women and sickle cell disease patients^{16,17} so hypo-

chromic microcytic cells in peripheral blood film review should not be assumed to be due to iron deficiency when iron studies have not been done.

Globin Chain Synthesis: This technique quantifies the amount of alpha and beta chains (/ ratio) by culturing peripheral blood reticulocytes in the presence of tritiated leucine. It helps to determine if there is an imbalance in the ratio of synthesis of the two globin chains. This test is better done in a reference laboratory with facilities for the use and disposal of radioactive materials. The ratio is less than one in alpha thalassaemia and greater than one in beta thalassaemia.

High Performance Liquid Chromatography (HPLC): This is an advanced technology used in separating the components of a mixture; it can thus be used to separate and quantify haemoglobins. For the analysis of haemoglobin variants, weak cation and anion-exchange columns are used while a reversed phase column are used for globin chain analysis. HPLC can be used primarily as a screening method or as a supplement to electrophoresis. The high cost is a disadvantage to the use of HPLC even though its results are reliable and reproducible; there could also be the technical problem of coeluting other haemoglobins with HbA₂ especially in the hands of the inexperienced.

Molecular Methods in the Diagnosis of Haemoglobinopathies
DNA analysis in the diagnosis of haemoglobinopathies even though undertaken in specialist referral centres is not done as a routine but mostly employed in prenatal diagnosis and in resolving diagnosis of difficult cases of haemoglobinopathies. Specimen for DNA analysis is obtained from white cells, chorionic tissue or amniocytes. Each mutation is detected by its own specific probes or primers. DNA analyses are based on Southern blot analysis or polymerase chain reaction (PCR) with emphasis shifting towards the use of PCR based techniques, Southern blot are still necessary in some situations. The three PCR based techniques used in diagnostic laboratories include (a) the hybridization of labelled allele specific oligonucleotide probes, to amplified DNA fixed to nylon filters by dot blotting¹⁸ or by reverse dot blotting with the probes fixed to the filters¹⁹; (b) the use of allele specific primers²⁰; and (c) agarose or polyacrylamide gel electrophoresis. The first two techniques detect point mutations and require a battery of specific probes one for every mutation likely to be encountered. There are many sources of errors with the use of the PCR which include contamination from previous samples or maternal contamination, non amplification of a desired segment and incomplete digestion of amplified product. Samples should therefore be handled with utmost care.

CONCLUSION

Primary health care facilities are closest to the communities; so should be able to screen for the haemoglobinopathies. Therefore, every patient presenting with a haematocrit less than 30% should be referred for secondary care, so also should all patients found to have a positive sickling test. These centres should have facilities to check the haematocrit of patients and a microscope for the sickling test. The staff should be trained to use the microscope for a sickling test and to check for hypochromia and microcytosis. Every general hospital on the other hand should be able to run electrophoresis at alkaline pH and have an automated cell counter to check the red cell indices of patients. Staff at these hospitals should also be able to interpret results from both equipment. While at the tertiary level, citrate agar electrophoresis or isoelectric focusing should be mandatory with DNA technology provided at designated tertiary centres in the geopolitical zones. Accurate diagnosis of the haemoglobinopathies is important in this community with a high prevalence of the sickle cell and thalassaemia syndromes. Each hospital should have technical staffs that are well trained to handle the specimens and should be able to decide when to refer diagnosis to a higher facility when difficulty arises. The need for quality control is also essential in the diagnosis of the haemoglobinopathies; apart from the inbuilt quality control of each procedure, laboratories should be a part of other external quality control programs.

REFERENCES

1. **Omotade O.O.**, Kayode C.M., Falade S.L. *et al.* Routine screening for sickle cell haemoglobinopathy by electrophoresis in an infant welfare clinic. *West Afr J Med* 1998;17:91-94
2. **Falusi A.G.**, Esan G.J and Ayubb H. Alpha thalassaemia in Nigeria: its interaction with sickle cell disease. *Eur J Haematol.*1987;38:370-375
3. **Esan G.J.F.** The thalassaemia syndrome in Nigeria. *Br J Haematol.* 1970;19:47-56
4. **Kotila T.R.** When the inheritance of two heterozygote states become a diagnostic problem: Misdiagnosis of the sickle cell trait. *Nig J Med* 2007;16:1-4
5. **Kotila T.R.**, Adeyemo A.A., Mewoyeka O.O. and Shokunbi W.A. Beta thalassaemia trait in Western Nigeria. *Afr Health Sci* 2009;9:46-48
6. **Esan G.J.F.** The essential laboratory investigation of sickle cell disease. In: *sickle cell disease: A handbook for the general clinician.* Ed AF Fleming. Edinburgh: Churchill Livingstone, 1982:33-41
7. British Committee for Standards in Haematology. Guidelines for investigation of the α and β thalassaemia traits. *J Clin Pathol* 1994;47:289-295
8. **Rathod A.A.**, Kaus A., Patel V. *et al.* Usefulness of cell counter based parameters and formulars in detection of α thalassaemia trait in areas of high prevalence. *Am J Pathol.* 2007;128:585-589
9. **Weatherall D.J.**, Clegg J.B. The thalassaemia syndromes. 3rd edn. Oxford: Blackwell Sci Publications, 1981
10. International Committee for Standardization in Haematology. Recommendations for selected methods for quantitative estimation of HbA2 and for HbA2 reference preparation. *Br J Haematol.* 1978;38:573-577
11. Efremov G.D. In: Huisman THJ, ed. *Methods in Haematology* No 15: the haemoglobinopathies. Edinburgh: Churchill Livingstone, 1986:72-90
12. **Alperin J.B.**, Dow P.A. and Petteway M.B. Haemoglobin A2 levels in health and various haematological disorders. *Am J Clin Pathol* 1972;67:219-26
13. **Betke K.**, Marti H.R. and Schlicht I. Estimation of small percentage of fetal haemoglobin. *Nature* 1959; 184:1877-1878
14. **Okan V.**, Cigiloglu A. and Cifa S. Red cell indices and functions differentiating patients with the beta thalassaemia trait from those of iron deficiency anaemia. *J Int Med Res.* 2009;37:25-30
15. **Beyan C.**, Kaptan K. and Ifran A. Predictive value of discriminating indices in differential diagnosis of iron deficiency and beta thalassaemia trait. *Eur J Haematol.* 2007;78:524-526
16. **Oluboyede O.A.**, Usanga E.A., Lukanmbi F.A. and Ajayi O.A. Evaluation of serum ferritin levels and other hematological parameters in a Nigerian population. *J Natl Med Assoc.* 1983; 75:885-889
17. **Abudu O.O.**, Macaulay K. and Oluboyede O.A. Serial evaluation of iron stores in pregnant Nigerians with hemoglobin SS or SC. *J Natl Assoc.*1990; 82:41-48

18. **Saiki R.K.**, Bugawan T.L., Horn G.T., *et al.* Analysis of enzymatically amplified β -globin and HLA-DQ alpha DNA with allele –specific oligonucleotide probes. *Nature* 1986;324:163-166
19. **Saiki R.K.**, Walsh P.S., Levenson C.H., *et al.* Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes. *Proc Natl Acad Sci USA* 1989;86:6230-6234
20. **Old J.M.**, Varawalla N.Y. and Weatherall D.J. The rapid detection and prenatal diagnosis of thalassemia in the Asian Indian and Cypriot populations in the UK. *Lancet* 1990;ii:834-837